• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Lantern Pharma Inc.

    4/3/26 10:53:30 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LTRN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Lantern Pharma Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)




    51654W101

    (CUSIP Number)
    03/30/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    51654W101


    1Names of Reporting Persons

    Thomas A. Satterfield, Jr.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    95,000.00
    6Shared Voting Power

    475,000.00
    7Sole Dispositive Power

    95,000.00
    8Shared Dispositive Power

    475,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    570,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  *Based on 11,254,697 shares of common stock of the issuer (the "Common Stock") outstanding as of March 13, 2026, as reported by the issuer in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Lantern Pharma Inc.
    (b)Address of issuer's principal executive offices:

    1920 McKinney Avenue, 7th Floor, Dallas, TX 75201
    Item 2. 
    (a)Name of person filing:

    Thomas A. Satterfield, Jr.
    (b)Address or principal business office or, if none, residence:

    15 Colley Cove Drive Gulf Breeze, Florida 32561
    (c)Citizenship:

    Incorporated by reference from Item 4 of the Cover Page.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP Number(s):

    51654W101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Incorporated by reference from Item 9 of the Cover Page.
    (b)Percent of class:

    Incorporated by reference from Item 11 of the Cover Page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Incorporated by reference from Item 5 of the Cover Page.

     (ii) Shared power to vote or to direct the vote:

    Incorporated by reference from Item 6 of the Cover Page.

     (iii) Sole power to dispose or to direct the disposition of:

    Incorporated by reference from Item 7 of the Cover Page.

     (iv) Shared power to dispose or to direct the disposition of:

    Incorporated by reference from Item 8 of the Cover Page.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    With respect to the beneficial ownership reported for Thomas A. Satterfield, Jr., 45,000 shares are held by Tomsat Investment & Trading Co., Inc., a corporation controlled by Mr. Satterfield and of which he serves as President; 250,000 shares are held by Caldwell Mill Opportunity Fund, LLC which fund is managed by an entity of which Mr. Satterfield owns a 50% interest and serves as Chief Investment Manager; 150,000 shares are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield; and 30,000 shares of common stock are held by Satterfield Vintage Investments, L.P. Tomsat Investment & Trading Co., Inc. and A.G. Family L.P. jointly own a majority of Satterfield Vintage Investments, L.P.'s equity, and Tomsat Investment & Trading Co., Inc. is the general partner of Satterfield Vintage Investments, L.P.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Thomas A. Satterfield, Jr.
     
    Signature:/s/ Thomas A. Satterfield, Jr.
    Name/Title:Thomas A. Satterfield, Jr.
    Date:04/03/2026
    Get the next $LTRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LTRN

    DatePrice TargetRatingAnalyst
    3/11/2022$34.00 → $36.00Buy
    HC Wainwright & Co.
    11/2/2021$32.00 → $34.00Buy
    HC Wainwright & Co.
    10/7/2021$32.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $LTRN
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Lantern Pharma Inc.

    SCHEDULE 13G - Lantern Pharma Inc. (0001763950) (Subject)

    4/3/26 10:53:30 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Lantern Pharma Inc.

    424B5 - Lantern Pharma Inc. (0001763950) (Filer)

    3/30/26 5:57:43 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Lantern Pharma Inc.

    10-K - Lantern Pharma Inc. (0001763950) (Filer)

    3/30/26 5:36:17 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Silberstein David S.

    4 - Lantern Pharma Inc. (0001763950) (Issuer)

    1/13/26 4:05:08 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Chandru Vijay

    4 - Lantern Pharma Inc. (0001763950) (Issuer)

    1/13/26 4:05:11 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Schalop Lee Troy

    4 - Lantern Pharma Inc. (0001763950) (Issuer)

    1/13/26 4:05:09 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026

    Briefing to Feature a Live Walkthrough, Demonstration of Key Features, The Market Opportunity & Industry Need, Competitive Positioning, and Platform Monetization Strategy Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern" or the "Company"), an AI-driven clinical-stage precision oncology company, today announced it will host an investor, analyst and shareholder briefing on Thursday, April 9, 2026 at 8:30 AM Eastern featuring a live demonstration of withZeta.ai — the world's first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, and clinical trial design. The briefing will be conducted via live webcast and will cover the platform's capabilities and

    4/2/26 8:10:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    Year of Clinical Validation and Strategic Expansion Across Pipeline, AI Platform Advances Towards Commercialization, and Global Trial Milestones LP-300 Phase 2 HARMONIC™ Trial Progress: Continued enrollment and patient follow-up across the United States, Japan, and Taiwan. Completion of targeted enrollment in Japan across five clinical sites including the National Cancer Center Tokyo. Preliminary data presented at the 66th Annual Meeting of the Japan Lung Cancer Society. Type C meeting package submitted to FDA in March 2026, with meeting scheduled for mid-May 2026 seeking feedback on proposed protocol amendments including focusing enrollment on EGFR exon 21 L858R patients and updating th

    3/30/26 4:05:00 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

    Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern" or the "Company"), an AI‑driven, clinical‑stage oncology company leveraging its proprietary RADR® platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on an unverified third‑party website. The third‑party article incorrectly claimed that Panna Sharma has stepped down as President and Chief Executive Officer of Lantern. This claim is false, entirely without basis, and appears designed to mislead investors. No such communication has been issued by the Company or its Board of Directors. Mr. Sharma continues to serve as President, Chief Execu

    3/27/26 7:23:00 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Lantern Pharma with a new price target

    HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $36.00 from $34.00 previously

    3/11/22 6:29:59 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Lantern Pharma with a new price target

    HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $34.00 from $32.00 previously

    11/2/21 6:34:51 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Lantern Pharma with a new price target

    HC Wainwright & Co. initiated coverage of Lantern Pharma with a rating of Buy and set a new price target of $32.00

    10/7/21 8:16:17 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Financials

    Live finance-specific insights

    View All

    Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    Year of Clinical Validation and Strategic Expansion Across Pipeline, AI Platform Advances Towards Commercialization, and Global Trial Milestones LP-300 Phase 2 HARMONIC™ Trial Progress: Continued enrollment and patient follow-up across the United States, Japan, and Taiwan. Completion of targeted enrollment in Japan across five clinical sites including the National Cancer Center Tokyo. Preliminary data presented at the 66th Annual Meeting of the Japan Lung Cancer Society. Type C meeting package submitted to FDA in March 2026, with meeting scheduled for mid-May 2026 seeking feedback on proposed protocol amendments including focusing enrollment on EGFR exon 21 L858R patients and updating th

    3/30/26 4:05:00 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET

    Webcast to be held Monday, March 30th, 4:30 p.m. ET, register for the webcast here, or at the link provided below.  Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its fourth quarter and fiscal year 2025 operating and financial results webcast on Monday, March 30, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial results for the fourth quarter and fiscal year ended December 31, 2025 and provide guidan

    3/23/26 4:30:00 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

    Transformational Quarter Marked by Clinical Validation, Regulatory Progress, and Strategic Momentum in Commercial AI Platform Launch LP-184 Phase 1a clinical trial results demonstrate all primary endpoints achieved with 48% clinical benefit rate in evaluable cancer patients at or above therapeutic dose threshold; marked tumor reductions observed in patients with DNA damage repair mutations including CHK2, ATM, and STK11/KEAP1 alterations. FDA Type C meeting completed, providing regulatory guidance and pathway clarity for Starlight Therapeutics' planned pediatric CNS cancer trial in Atypical Teratoid Rhabdoid Tumor (ATRT) and confirming spironolactone combination strategy. LP-300 pr

    11/13/25 8:30:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Leadership Updates

    Live Leadership Updates

    View All

    Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

    Seasoned Biotech Executive & Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member

    7/28/25 8:00:00 AM ET
    $CMRX
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives

    DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced the addition of two senior industry executives to support the Company's clinical and manufacturing initiatives. Dr. Harry Kochat has been appointed Senior Director of Chemistry, Manufacturing and Controls (CMC) and Manufacturing Quality Affairs, where his responsibilities will include oversight of drug candidate manufacturing and quality control. Darlene Bunpian, MPH has been appointed Clinical Trial Project Manag

    9/2/21 8:59:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Lantern Pharma Inc. (Amendment)

    SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)

    3/1/24 4:10:40 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lantern Pharma Inc. (Amendment)

    SC 13G/A - Lantern Pharma Inc. (0001763950) (Subject)

    2/14/24 4:05:49 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lantern Pharma Inc. (Amendment)

    SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)

    12/1/23 6:02:25 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care